HCPCS Level II · Drugs administered other than oral method
J0651Injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J0651
J0651 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, levothyroxine sodium (fresenius kabi), not therapeutically equivalent to j0650, 10 mcg.
It was added to HCPCS effective 04/01/2024, and its current record took effect 07/01/2024.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, levothyroxine, freskabi
- Date added
- 04/01/2024
- Action effective
- 07/01/2024
- BETOS
- O1E
Related J06xx codes
- J0600Injection, edetate calcium disodium, up to 1000 mg
- J0601Sevelamer carbonate (renvela or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0602Sevelamer carbonate (renvela or therapeutically equivalent), oral, powder, 20 mg (for esrd on dialysis)
- J0603Sevelamer hydrochloride (renagel or therapeutically equivalent), oral, 20 mg (for esrd on dialysis)
- J0604Cinacalcet, oral, 1 mg, (for esrd on dialysis)
- J0605Sucroferric oxyhydroxide, oral, 5 mg (for esrd on dialysis)
- J0606Injection, etelcalcetide, 0.1 mg
- J0607Lanthanum carbonate, oral, 5 mg (for esrd on dialysis)
- J0608Lanthanum carbonate, oral, powder, 5 mg, not therapeutically equivalent to j0607 (for esrd on dialysis)
- J0609Ferric citrate, oral, 3 mg ferric iron, (for esrd on dialysis)
- J0612Injection, calcium gluconate, not otherwise specified, 10 mg
- J0613Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg
Common questions about J0651
Is HCPCS J0651 still valid?
- Yes. J0651 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J0651?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.